Hyaluronidase Via LADD Scleroderma-induced Microstomia
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Two treatment methods, ablative carbon dioxide (CO2) laser and intradermal hyaluronidase,
will be combined to maximize the beneficial potential of each. Laser-assisted drug delivery
(LADD) has been shown to be effective for the administration of medications in diverse skin
diseases but not previously reported for the treatment of scleroderma-induced microstomia. By
using this laser technique, the investigator can reduce the pain of typical hyaluronidase
injections and reap the therapeutic benefit of the laser treatment itself. The investigator's
goal is to create greater mouth mobility for chewing and speaking as well as improved oral
hygiene, self-esteem, and overall quality of life. Each participant will undergo three
separate laser sessions at 4 to 8-week intervals. Participants will also complete a follow-up
visit three months after the last laser session to evaluate the response.